A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical ASP-1001 (Contrast Media Formulation) in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (NAC).

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical ASP-1001 (Contrast Media Formulation) in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (NAC).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Jul 2013

At a glance

  • Drugs ASP 1001 (Primary)
  • Indications Allergic rhinitis; Grass pollen hypersensitivity; Hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top